Weekly updateCompaniesRecruiting servicePost a job
Lycia Therapeutics

Lycia Therapeutics

    Company info:

  • 1-50
  • 2020
  • San Francisco, CA
  • 100-500M



Claim company profile

About company:

Lycia Therapeutics is developing tools to degrade extracellular proteins exploiting knowledge of lysosomes. Lysosomes are cellular organelles that are hubs for protein degradation. Using their Lysosomal Targeting Chimera (LYTAC) platform, Lycia is hijacking the endogenous lysosomal trafficking shuttle to target the untapped extracellular proteome. The LYTAC platform can be extended to both board-based and tissue-specific targeting enabling several therapeutic modalities. Lycia is advancing an undisclosed discovery pipeline of novel LYTAC degraders for clearing protein aggregates and immune complexes, removal of circulating antibodies and degrading challenging membrane targets to treat autoimmune and inflammatory diseases.


Lycia Therapeutics
Associate Director/Director, Business Development
San Francisco, CA|13 days ago
Lycia Therapeutics
Scientist ll, Purification
San Francisco, CA|33 days ago
Lycia Therapeutics
Sr. Director/Exec. Director, Translational Medicine
San Francisco, CA|100+ days ago

© 2023 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com